First centre in France — Paris 17th arrondissement

Stimulating the brain,
preserving memory and independence

The Neurolith® by Storz Medical delivers ultra-short, low-energy acoustic pulses to stimulate neurons non-invasively, without pain and with no serious adverse event reported.

Non-invasive No serious adverse event reported CE marking — Alzheimer's disease Neurolith® Storz Medical
Book a consultation Discover TPS ☎ 06 64 99 83 10
~80%
positive clinical response — observational data (Düsseldorf)
6
sessions over 2 weeks — 3 sessions/week · Storz protocol
0
serious adverse event reported across all published studies

These data come from the published studies and from the clinical experience of the Düsseldorf reference centre (5 years of activity). This device is not a substitute for specialist medical follow-up.

The technology

What are TPS (Transcranial Pulse Stimulation)
and the Neurolith®?

TPS (Transcranial Pulse Stimulation) is a non-invasive neuromodulation technique using mechanical waves — ultra-short acoustic pulses (3 µs) at low energy (0.1–0.25 mJ/mm²) — to selectively stimulate target brain structures (art. R4321-7 of the French Public Health Code).

Guided by the patient's MRI, the Neurolith® by Storz Medical delivers these pulses with millimetric precision, reaching areas inaccessible to other ultrasound stimulation techniques.

Unlike rTMS or tDCS, this ultrasound neuromodulation technique allows three-dimensional stimulation at depth, including the hippocampus, the medial prefrontal cortex and the basal ganglia — structures directly involved in Alzheimer's disease, Parkinson's disease and treatment-resistant depression.

A session lasts about 45 minutes; the patient is seated and feels no pain. No anaesthesia and no drug preparation are required.

Mechanotransduction

Acoustic shockwaves exert mechanical forces on cell membranes, activating intracellular signalling pathways and stimulating the production of growth factors.

Angiogenesis & revascularisation

Stimulation of VEGF production, promoting the formation of new vessels and improved local cerebral perfusion in the targeted areas.

Nitric oxide (NO)

Production of endogenous NO inducing local vasodilation and an anti-inflammatory action, improving the oxygenation of the target brain tissues.

Neurotrophins (BDNF, NGF, FGF-2)

Release of neurotrophic factors promoting neuronal survival, neurite growth and the repair of damaged synaptic circuits.

Neurogenesis

Stimulation of the production of new neurons in the hippocampus and promotion of their integration into existing circuits — a region critical for memory.

Synaptic plasticity (LTP)

Induction of long-term potentiation mechanisms, strengthening synaptic connections and improving the efficiency of the neural networks involved in cognitive functions.

Functional indications

Transcranial Pulse Stimulation: indications — Alzheimer's disease (CE marking) and other uses

The centre offers neuromodulation programmes using Transcranial Pulse Stimulation (TPS) after clinical assessment and verification that there is no contraindication. A favourable opinion from the neurologist or treating physician is systematically required before any protocol.

Alzheimer's disease — CE-marked indication. The Neurolith® holds a CE marking for the stimulation of the central nervous system in patients with Alzheimer's disease. The centre applies the protocol derived from the published studies, with a standardised assessment at entry and at discharge.
Other indications — off-label framework. For the other situations (Parkinson's disease, treatment-resistant depression, essential tremor, ADHD, post-stroke…), TPS is used outside the CE indication (off-label): the technique is the subject of ongoing research, its effects are under evaluation, and it is not a validated or curative treatment. Every off-label programme is therefore conducted with the rigour of a research protocol: prior opinion from the neurologist or the treating physician, standardised assessments before and after, traceability of results, monitoring of adverse events, and a report sent to your physician.
01
Cognitive impairment — Alzheimer's disease
✓ CE marking

Helping to preserve memory, language and day-to-day independence. Rehabilitation of impaired cognitive functions (memory, attention, executive functions) through targeted ultrasound stimulation. Assessment with MoCA, STROOP, BDI-II.

02
Motor disorders — Parkinson's disease
Outside CE indication · off-label

Aiming for greater ease in everyday movements — walking, writing, mobility. Functional rehabilitation of motor disorders (tremor, rigidity, bradykinesia) through ultrasound stimulation. Assessment with MDS-UPDRS III and BDI-II.

03
Mood disorders — Treatment-resistant depression
Outside CE indication · off-label

Supporting the return of drive, attention and emotional balance. Functional rehabilitation of attentional and emotional-regulation capacities, alongside psychiatric follow-up.

04
Early cognitive impairment — MCI
Extension of the Alzheimer's indication

Acting early, when there is most capacity left to preserve. Early functional rehabilitation of executive and memory functions. Preservation of residual functional capacities.

05
Attention disorders — Adult ADHD
Outside CE indication · off-label

Helping to improve concentration and attentional stability. Rehabilitation of sustained attention and working memory through ultrasound stimulation. Neuropsychological assessment before and after. (Exploratory indication — preliminary data.)

06
Cognitive impairment — Lewy body disease
Outside CE indication · off-label

Supporting cognitive abilities and behaviour in daily life. Rehabilitation of impaired cognitive and behavioural functions. Functional support complementing neurological follow-up. (Exploratory indication — preliminary data, by extension from the Alzheimer's findings.)

07
Motor disorders — Essential tremor
Outside CE indication · off-label

Aiming for a steadier, more precise movement. Functional rehabilitation of motor control. Assessment with the ETRS scale before and after the rehabilitation programme.

08
Other functional impairments
Outside CE indication · off-label

Functional recovery after ischaemic stroke (> 6 months), neurological post-COVID syndrome, MSA, central neuropathic pain. (Exploratory indications — preliminary data only.)

In practice

What does a session involve?

⏱
About 45 minutes
A standardised assessment is included at the first and at the last session.
🪑
Seated, pain-free
You are comfortably seated; the stimulation is painless.
💊
No anaesthesia, no medication
No drug preparation is required.
🚶
Outpatient
You leave as usual after the session and resume your activities.
How the care pathway is organised

Protocol and course of care

0
Pre-registration
Automatic Doctolib mailing: TPS information sheet + exclusion criteria + pre-session questionnaire
1
Information & file
TPS information sheet + contraindications sent by email · phone call available if needed · consent signed at session 1
2
Session 1 + Initial assessment
Baseline assessments tailored to the condition (~45 min) · MRI-based planning · 1st TPS stimulation
3
Sessions 2 to 5
3 sessions/week × 2 weeks · 45 min/session · systematic tolerance check
4
Session 6 + Discharge assessment
Same tests as at entry · TPS session · report sent to the referring physician
5
Boosts (if indicated)
Maintenance sessions every ~6 weeks · automatic reminders + repeat testing
Full initial protocol
2 000 €
Entry assessment + 6 TPS sessions (3/week × 2 weeks) + discharge assessment + report to your physician
Maintenance boost session
300 €
Quick repeat test included · every ~6 weeks · automatic Doctolib reminders

Not covered by the French national health insurance (Assurance Maladie) · payment in instalments possible

Some functional impairments — in particular severe mood disorders and advanced forms of cognitive or motor impairment — may require 10 to 12 sessions according to the data in the literature. A personalised quote is systematically provided at the first consultation, so that the rehabilitation programme can be adapted to the available scientific evidence and to each patient's clinical situation.

Our equipment
Neurolith®
by Storz Medical

The only TPS medical device with MRI guidance (BodyTrack®) for precision brain targeting down to 8 cm in depth.

Storz Medical AG  ·  Tägerwilen  ·  Switzerland
Neurolith® — Storz Medical — Centre TPS Paris 17
Video

The Neurolith® in operation

Official presentation video of the device by Storz Medical.

© Storz Medical AG

Scientific data

A growing body of evidence

Cognitive impairment — key studies

The clinical trials published in leading journals (including JAMA Network Open) confirm the efficacy of ultrasound stimulation for the rehabilitation of cognitive functions, with improvements documented in the short and medium term using standardised instruments (CERAD CTS, ADAS-Cog, MoCA).

Study Main finding
Beisteiner et al., Advanced Science 2019
Pilot study		 Significant improvements, stable at 3 months (CERAD, MoCA, MMSE)
Matt et al., JAMA Network Open 2025
Double-blind RCT — 60 patients		 +3.91 pts CERAD CTS at 3 months (≤70-year subgroup, vs −1.83 sham)
Cont et al., Düsseldorf
Real-world cohort		 +15.76% total ADAS score
+8.65% ADAS cognitive

Motor disorders & Mood disorders

Specific rehabilitation programmes have shown a significant reduction in motor impairment as measured by the UPDRS-III. The centre follows a rigorous scientific approach: a standardised assessment at entry and at discharge, contributing to the international database.

Study Main finding
Cont et al., Frontiers in Neurology 2024
20 patients, 10 sessions		 UPDRS-III: 16.70 → 12.95 (p < 0.001, Cohen's d = 1.38)
−22% motor symptoms
Gianlorenco et al., Journal of Neurology 2026
Harvard Medical School — Spaulding / Mass General Brigham (Prof. Fregni), 14 patients		 Total UPDRS −21.4% (maintained at 1 month)
Cognition +25%, depression −40%, improved quality of life
All published studies 0 serious adverse event reported
~80%

positive clinical response (improvement or stabilisation) — unpublished observational data from the Düsseldorf reference centre, 5 years of activity

The practitioner

Expertise at the crossroads
of physiotherapy and neuroscience

Charles du Teil — Physiotherapist and Osteopath — Centre TPS Paris 17
Charles du Teil
Physiotherapist – Osteopath D.O.

A physiotherapist and osteopath for 18 years, based at 7 rue Anatole de la Forge, Paris 17th, I devote a growing part of my practice to the neuromodulation of cognitive and motor impairments of neurological origin.

Trained in the TPS technique in Düsseldorf with Prof. Sprick, Dr Günes and the Storz Medical teams, pioneers of this approach in Germany, I chose to create the first TPS neuromodulation centre in France in order to offer my patients with Alzheimer's disease, Parkinson's disease or treatment-resistant depression a serious option, based on the published data, with no serious adverse event reported in the studies.

Düsseldorf training Prof. Sprick Dr Günes Storz Medical

This project grew out of a conviction: patients with cognitive or motor impairments of neurological origin deserve access to the most advanced rehabilitation techniques as soon as those techniques show a satisfactory safety profile and measurable results.

The rehabilitation programme offered is structured, reproducible and documented. Every patient receives a standardised assessment before and after rehabilitation. A full report is sent to the referring physician at the end of the programme.

I work in close collaboration with the neurologists and psychiatrists who follow my patients, and I undertake not to treat any patient whose profile is not compatible with TPS.

"To give every patient the best possible chance of preserving and restoring their functional capacities, through scientifically evaluated rehabilitation techniques, within an ethical and rigorous framework."
For healthcare professionals

Referring a patient?

Download our information letter for physicians and our referral form

Contact us Download the physician brochure (PDF)
Frequently asked questions

Frequently Asked Questions — TPS & Neuromodulation

What is Transcranial Pulse Stimulation (TPS)?
TPS is a non-invasive neuromodulation technique that uses mechanical waves (ultra-short acoustic pulses of 3 microseconds) guided by MRI to stimulate target brain areas. The device used is the Neurolith® by Storz Medical, a CE-certified Class IIb medical device. A favourable opinion from the neurologist or treating physician is systematically required before any protocol.
What does “outside the CE indication (off-label)” mean?
The CE marking of the Neurolith® covers Alzheimer's disease. For the other situations (Parkinson's disease, treatment-resistant depression, essential tremor, ADHD…), TPS is used “off-label”: the technique is the subject of ongoing research and its effects are under evaluation — it is not a validated or curative treatment. This does not mean improvised practice: every off-label programme requires the prior opinion of your neurologist or treating physician, relies on standardised assessments before and after, and is subject to traceability of results and monitoring of adverse events, with a report sent to your physician.
Which conditions are treated?
Centre TPS Paris 17 treats patients presenting with:
  • Indication covered by the CE marking: Alzheimer's disease (and early MCI, by extension)
  • Indications outside the CE marking — off-label use, for experimental purposes (effects under evaluation, preliminary data): Parkinson's disease, treatment-resistant depression, Lewy body dementia, essential tremor, MSA, adult ADHD, post-stroke, neurological post-COVID
Is TPS painful?
No, TPS is painless and non-invasive. The patient feels light tapping on the skull. In the published clinical studies (Matt et al., JAMA Network Open 2025), no serious adverse event was reported. About one third of patients report mild, transient headaches, which resolve spontaneously within 24 hours.
How much does a TPS protocol cost? Is it reimbursed?
The full initial protocol (6 sessions, including the entry and discharge assessments) is priced at 2 000 €. Maintenance boost sessions cost 300 €. TPS is not reimbursed by the French national health insurance (Assurance Maladie). Payment in instalments is possible on request. Some complementary health insurers cover part of the cost — check with yours.
How does a TPS protocol work?
Our protocols are designed to follow the scientific literature as closely as possible. The initial programme comprises 6 sessions over 2 weeks (3 sessions per week). For Parkinson's disease, protocols may extend to 10 sessions with the patient's agreement, in line with the published data. Each session lasts about 45 minutes. The first session includes standardised assessments (MoCA, Stroop, BDI-II for cognitive impairment; MDS-UPDRS III for motor disorders). The last session includes the discharge assessment, and a report is sent to the referring physician. Maintenance sessions every 4 to 6 weeks may be recommended.
Is a prescription required for TPS?
A prescription is not required, as TPS is not reimbursed by the French national health insurance (Assurance Maladie). However, a favourable opinion from the neurologist or treating physician is systematically required before starting any protocol. If you do not have a referring physician, we can point you in the right direction.
What results can be expected from TPS?
Results vary according to the condition, the stage of the disease and the patient. The clinical studies published in international peer-reviewed journals report:

Alzheimer's disease:
  • Significant improvement in the CERAD score: +3.91 points on average in patients ≤70 years at 3 months, versus −1.83 points under sham stimulation (double-blind randomised trial, 60 patients, Matt et al., JAMA Network Open, 2025)
  • Improvement in memory, verbal communication and spatial orientation (Beisteiner et al., Advanced Science, 2020)
  • Signs of reduced cortical atrophy in critical brain regions (Popescu et al., Alzheimer's & Dementia, 2021)
  • Effects maintained for at least 3 months, and up to 12 months with maintenance sessions (Cont et al., Frontiers in Neurology, 2022)
Parkinson's disease:
  • Significant improvement in the UPDRS-III motor score: from 16.70 to 12.95 on average (p < 0.001), i.e. a large effect size (Cohen's d = 1.38) in 20 patients, 10 sessions (Cont et al., Frontiers in Neurology, 2024)
  • Reduction of resting tremor after a single session (Manganotti et al., Brain Research, 2025)
Depression:
  • Significant reduction in the BDI-II score (Beck Depression Inventory) in Alzheimer's patients with comorbid depression, maintained at 3 months (Matt et al., Alzheimer's & Dementia, 2022)
TPS is an add-on treatment: it does not cure the disease but may improve functional capacities and quality of life. A neuropsychological assessment before and after makes it possible to measure the results objectively for each patient.
Are there contraindications to TPS?
Yes, the main contraindications are:
  • Active malignant brain tumour
  • Metallic intracranial implant (clips, DBS electrodes…)
  • Pacemaker or implantable defibrillator
  • Uncontrolled epilepsy (less than 3 months)
  • Pregnancy (current or suspected)
  • Active thrombosis
  • Corticosteroid therapy within the previous 6 weeks
  • Haemophilia or coagulation disorders
The presence of a contraindication does not necessarily mean that the protocol is impossible — it calls for a further evaluation. These criteria are checked in the pre-session questionnaire and at the entry assessment.
What is the difference between TPS and rTMS?
TPS (Transcranial Pulse Stimulation) uses mechanical waves (acoustic pulses) to stimulate the brain, whereas rTMS (repetitive Transcranial Magnetic Stimulation) uses magnetic fields. Main differences:
  • TPS penetrates more deeply into brain tissue (up to 8 cm vs 2-3 cm for rTMS)
  • TPS is guided by MRI in real time, allowing precise targeting of the areas to be stimulated
  • TPS uses mechanical waves (no electromagnetic field)
  • The TPS protocol is shorter (6 sessions vs 20-30 for rTMS)
Can I continue my medication during TPS?
Yes, in the vast majority of cases. TPS is compatible with common drug treatments (cholinesterase inhibitors, memantine, L-DOPA, antidepressants). There is no need to interrupt your treatment. Coagulation disorders and anticoagulant treatment at therapeutic doses must be reported and assessed on a case-by-case basis. Your prescribing physician and the physiotherapist assess compatibility together.
How do I book an appointment at Centre TPS Paris 17?
You can book an appointment: The centre is located at 7 rue Anatole de la Forge, 75017 Paris (Metro Argentine L1 — 3 min walk). Please remember to bring a recent brain MRI.
Is TPS effective for Alzheimer's disease?
The clinical studies show encouraging results. The randomised controlled trial by Matt et al. (JAMA Network Open, 2025) in 60 patients demonstrated a significant improvement in the CERAD score (+3.91 points in patients ≤70 years at 3 months, versus −1.83 under sham). The pioneering study by Beisteiner et al. (2020) in Advanced Science had already reported improvements in memory, verbal communication and spatial orientation after 6 sessions. Popescu et al. (Alzheimer's & Dementia, 2021) observed signs of reduced cortical atrophy. TPS does not cure the disease but may slow cognitive decline and improve day-to-day independence.
Find us

Contact & Appointments

Address
7 rue Anatole de la Forge
75017 Paris
Booking
Via Doctolib (link below)
or by phone on 06 64 99 83 10
Centre opening
18 March 2026
Getting here
Metro: Argentine (L1) — 3 min walk
Charles de Gaulle–Étoile (L1, L2, L6) · RER A
Bus: 22, 30, 52, 73, 92
Book on Doctolib
Before your first session
Pre-session medical questionnaire
To be completed online before your initial assessment. No login required, takes 5 minutes.
Complete the questionnaire →

Information request